$PTGX
Protagonist Therapeutics, Inc

2017 Q1 Form 10-K Financial Statement

#000119312517073383 Filed on March 07, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.990M $2.570M $6.960M
YoY Change 110.56% 217.28% 135.14%
% of Gross Profit
Research & Development $11.28M $8.820M $25.71M
YoY Change 100.57% 110.5% 117.27%
% of Gross Profit
Depreciation & Amortization $88.00K $80.00K $317.0K
YoY Change 20.55% -11.11% 28.34%
% of Gross Profit
Operating Expenses $14.27M $11.40M $32.67M
YoY Change 102.74% 128.0% 120.81%
Operating Profit -$14.27M -$11.40M -$32.67M
YoY Change 102.74% 127.89% 120.81%
Interest Expense $170.0K $150.0K -$4.480M
YoY Change -103.61% -130.61% 7366.67%
% of Operating Profit
Other Income/Expense, Net $0.00 -$34.00K
YoY Change
Pretax Income -$14.10M -$11.25M -$34.98M
YoY Change 20.0% 104.92% 233.65%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.10M -$11.25M -$37.18M
YoY Change 20.04% 104.77% 150.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$840.8K -$767.4K -$2.536M
COMMON SHARES
Basic Shares Outstanding 16.79M shares 16.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.20M $77.60M $77.60M
YoY Change 117.93% 552.1% 552.1%
Cash & Equivalents $9.517M $21.08M $21.10M
Short-Term Investments $53.70M $56.50M $56.50M
Other Short-Term Assets $1.800M $906.0K $3.400M
YoY Change 200.0% 197.05% 112.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $67.55M $83.24M $83.20M
YoY Change 118.6% 485.98% 485.92%
LONG-TERM ASSETS
Property, Plant & Equipment $641.0K $562.0K $600.0K
YoY Change -19.88% -7.72% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $14.00M $10.20M $10.20M
YoY Change
Other Assets $34.00K $34.00K $0.00
YoY Change -83.0% 13.33%
Total Long-Term Assets $15.13M $10.75M $10.80M
YoY Change 1412.5% 1581.69% 1700.0%
TOTAL ASSETS
Total Short-Term Assets $67.55M $83.24M $83.20M
Total Long-Term Assets $15.13M $10.75M $10.80M
Total Assets $82.67M $93.99M $94.00M
YoY Change 159.16% 533.14% 535.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.132M $1.163M $1.200M
YoY Change -40.42% -6.74% 0.0%
Accrued Expenses $6.647M $5.272M $5.000M
YoY Change 189.0% 180.57% 194.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.779M $6.435M $6.400M
YoY Change 72.87% 105.85% 106.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.779M $6.435M $6.400M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $7.800M $6.435M $6.400M
YoY Change 41.82% 22.59% 23.08%
SHAREHOLDERS EQUITY
Retained Earnings -$78.70M -$64.59M
YoY Change 135.6%
Common Stock $153.6M $152.4M
YoY Change 129046.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.89M $87.56M $87.60M
YoY Change
Total Liabilities & Shareholders Equity $82.67M $93.99M $94.00M
YoY Change 159.16% 533.14% 535.14%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$14.10M -$11.25M -$37.18M
YoY Change 20.04% 104.77% 150.22%
Depreciation, Depletion And Amortization $88.00K $80.00K $317.0K
YoY Change 20.55% -11.11% 28.34%
Cash From Operating Activities -$10.36M -$9.680M -$29.97M
YoY Change 97.71% 104.22% 108.27%
INVESTING ACTIVITIES
Capital Expenditures $48.00K -$50.00K $379.0K
YoY Change -80.88% -77.27% -5.01%
Acquisitions
YoY Change
Other Investing Activities -$1.200M -$64.27M -$58.95M
YoY Change -116.22% 716.65% 649.05%
Cash From Investing Activities -$1.250M -$64.33M -$59.33M
YoY Change -117.48% 696.16% 618.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 370.0K -850.0K 106.3M
YoY Change -98.37% 510.28%
NET CHANGE
Cash From Operating Activities -10.36M -9.680M -29.97M
Cash From Investing Activities -1.250M -64.33M -59.33M
Cash From Financing Activities 370.0K -850.0K 106.3M
Net Change In Cash -11.24M -74.86M 17.01M
YoY Change -145.8% 483.93% -425.24%
FREE CASH FLOW
Cash From Operating Activities -$10.36M -$9.680M -$29.97M
Capital Expenditures $48.00K -$50.00K $379.0K
Free Cash Flow -$10.41M -$9.630M -$30.35M
YoY Change 89.55% 113.05% 105.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 ptgx Remeasured Fair Value Of Warrants
RemeasuredFairValueOfWarrants
1000000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1100000
CY2016Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8577571 shares
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2136000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
293000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10571000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
118000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
7868000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16787990 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
0
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1394000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
272409 shares
CY2015Q4 us-gaap Assets
Assets
14845000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
272409 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9324000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-12621000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10004000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1031000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4055000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6579361 shares
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1247000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
754000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
285000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-102000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10571000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9513000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1879000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2123000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
305000
CY2015Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1879000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities
Liabilities
5249000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14845000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3126000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
149000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
609000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1640000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-27400000
CY2015Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
41538000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
36996000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
805000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27416000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1558000
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10000
CY2015Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
126374911 shares
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
77185117 shares
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
77185117 shares
CY2015Q4 ptgx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
480000
CY2015Q4 ptgx Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
77185117 shares
CY2015Q4 ptgx Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
10009000
CY2015Q4 ptgx Cash Equivalents And Available For Sale Securities Gross Unrealized Loss
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss
5000
CY2015Q4 ptgx Cash Equivalents And Available For Sale Securities Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesFairValue
10004000
CY2015Q4 ptgx Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
715000
CY2015Q4 ptgx Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
1643000
CY2015Q4 ptgx Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
480000
CY2015Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
976000
CY2015Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
1253000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
10150000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
85169000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
600000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1313000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16722280 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16722280 shares
CY2016Q4 us-gaap Assets
Assets
93990000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Assets Current
AssetsCurrent
83244000
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18504000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
908000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23971000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12600000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
152393000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
56515000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21084000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2558157 shares
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1163000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1420000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1143000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-245000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23971000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21501000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5272000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
455000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
906000
CY2016Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
5272000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
368000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities
Liabilities
6435000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93990000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6435000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
235000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
87000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
562000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1875000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
87555000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2131000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64593000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3394000
CY2016Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10000
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2016Q4 us-gaap Security Deposit
SecurityDeposit
30000
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2016Q4 ptgx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
419000
CY2016Q4 ptgx Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
85241000
CY2016Q4 ptgx Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
2000
CY2016Q4 ptgx Cash Equivalents And Available For Sale Securities Gross Unrealized Loss
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss
74000
CY2016Q4 ptgx Cash Equivalents And Available For Sale Securities Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesFairValue
85169000
CY2016Q4 ptgx Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
2241000
CY2016Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
3617000
CY2016Q4 ptgx Prepaid Manufacturing Of Clinical Materials
PrepaidManufacturingOfClinicalMaterials
2488000
CY2016Q4 ptgx Cash And Cash Equivalents And Available For Sale Securities
CashAndCashEquivalentsAndAvailableForSaleSecurities
87700000
CY2016Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.06896 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.007 pure
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
872000
CY2014Q3 ptgx Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability
SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability
2300000
CY2016Q1 ptgx Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability
SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability
5800000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3651001 shares
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
864000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-49.38
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041 pure
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.265 pure
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1860000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-97000
CY2014 us-gaap Depreciation
Depreciation
258000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
258000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11126000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
184000
CY2014 us-gaap Operating Expenses
OperatingExpenses
9319000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-11072000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-299000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-54000
CY2014 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
218000
CY2014 us-gaap Increase In Carrying Amount Of Redeemable Preferred Stock
IncreaseInCarryingAmountOfRedeemablePreferredStock
146000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9515000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1557000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
179000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-604000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11218000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-9319000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9003000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2900000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7743000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.068 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7459000
CY2014 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
9000000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.647 pure
CY2014 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
146000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.82
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189 pure
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
99000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5269000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-59.32
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.027 pure
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.199 pure
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2963000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-39000
CY2015 us-gaap Depreciation
Depreciation
247000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14860000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
42000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2014 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
146000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
227197 shares
CY2014 ptgx Effective Income Tax Rate Reconciliation Warrant Revaluation
EffectiveIncomeTaxRateReconciliationWarrantRevaluation
-0.055 pure
CY2014 ptgx Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability
SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability
2308000
CY2014 ptgx Fair Value Adjustment Of Tranche Liability
FairValueAdjustmentOfTrancheLiability
897000
CY2014 ptgx Fair Value Adjustment Of Tranche And Warrants
FairValueAdjustmentOfTrancheAndWarrants
1769000
CY2014 ptgx Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
-259000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6432142 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006 pure
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-543000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
280000
CY2015 us-gaap Operating Expenses
OperatingExpenses
14794000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-14858000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8264000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2015 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
878000
CY2015 us-gaap Increase In Carrying Amount Of Redeemable Preferred Stock
IncreaseInCarryingAmountOfRedeemablePreferredStock
75000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10483000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4375000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
898000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1502000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14933000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-14794000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
7865000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17419000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
30000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3000000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17029000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14385000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
399000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0158 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.118 pure
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
690000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
115000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11831000
CY2015 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
17362000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
57000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.598 pure
CY2015 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
75000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0157 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
99000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
75000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
251717 shares
CY2015 ptgx Effective Income Tax Rate Reconciliation Warrant Revaluation
EffectiveIncomeTaxRateReconciliationWarrantRevaluation
-0.002 pure
CY2015 ptgx Fair Value Adjustment Of Tranche Liability
FairValueAdjustmentOfTrancheLiability
626000
CY2015 ptgx Fair Value Adjustment Of Tranche And Warrants
FairValueAdjustmentOfTrancheAndWarrants
83000
CY2015 ptgx Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
192000
CY2015 ptgx Reclassification To Redeemable Convertible Preferred Stock Tranche Liability
ReclassificationToRedeemableConvertiblePreferredStockTrancheLiability
1017000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-117000
CY2016 dei Entity Registrant Name
EntityRegistrantName
PROTAGONIST THERAPEUTICS, INC.
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2393829 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001377121
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2130000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.80
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065 pure
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
66904000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2130000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.360 pure
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6961000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and available-for-sale securities. Substantially all the Company&#x2019;s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</p> </div>
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
22000
CY2016 us-gaap Depreciation
Depreciation
317000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
317000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37320000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.014 pure
CY2016 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
525000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M13D
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
408000
CY2016 us-gaap Operating Expenses
OperatingExpenses
32666000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-37177000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-59328000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14188000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-76000
CY2016 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-67000
CY2016 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3395000
CY2016 us-gaap Increase In Carrying Amount Of Redeemable Preferred Stock
IncreaseInCarryingAmountOfRedeemablePreferredStock
558000
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
83648000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-34977000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2200000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-115000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1800000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37735000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-143000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-32666000
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
73169000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
106307000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-34000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
242000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13400000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29972000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0179 pure
CY2016 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
379000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
32000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accruals for research and development activities, fair value of redeemable convertible preferred stock tranche liability, fair value of redeemable convertible preferred stock warrant liability, fair value of common stock, stock-based compensation and income taxes. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</p> </div>
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.016 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.648 pure
CY2016 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In July 2016, the Company's board of directors approved an amendment to the Company's amended and restated certificate of incorporation to effect a reverse split of the Company's issued and outstanding common stock at a 1-for-14.5 ratio, which was effected on August 1, 2016.
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
707000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
66904000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
619000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83648000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
151000
CY2016 dei Trading Symbol
TradingSymbol
PTGX
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25705000
CY2016 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
22488000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
151000
CY2016 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
558000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
169000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0127 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.20
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2130000
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
558000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.625 pure
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6501796 shares
CY2016 ptgx Operating Lease Expiration Dates
OperatingLeaseExpirationDates
2018-04
CY2016 ptgx Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2016-08-01
CY2016 ptgx Operating Leases Commencement Date
OperatingLeasesCommencementDate
2017-07-01
CY2016 ptgx Effective Income Tax Rate Reconciliation Warrant Revaluation
EffectiveIncomeTaxRateReconciliationWarrantRevaluation
-0.043 pure
CY2016 ptgx Reclassification Of Preferred Stock Warrant Liability To Equity
ReclassificationOfPreferredStockWarrantLiabilityToEquity
1005000
CY2016 ptgx Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability
SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability
5837000
CY2016 ptgx Fair Value Adjustment Of Tranche Liability
FairValueAdjustmentOfTrancheLiability
4194000
CY2016 ptgx Fair Value Adjustment Of Tranche And Warrants
FairValueAdjustmentOfTrancheAndWarrants
4719000
CY2016 ptgx Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
1588000
CY2016 ptgx Deferred Tax Assets Operating Loss Carryforwards Domestic Expiration Period Start
DeferredTaxAssetsOperatingLossCarryforwardsDomesticExpirationPeriodStart
2035
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.75
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2697000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2689000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.78
CY2016 ptgx Temporary Equity Redemption Date Earliest
TemporaryEquityRedemptionDateEarliest
2022-07
CY2016 ptgx Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
SettlementOfFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
5837000
CY2016 ptgx Proceeds From Issuance Of Redeemable Convertible Preferred Stock Upon Exercise Of Preferred Stock Warrant Liability
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockUponExerciseOfPreferredStockWarrantLiability
20000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3219000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3083000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-40.96
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-11747000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7040000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.07
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-7098000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7091000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.79
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3449000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4021000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7084000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7138000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-20.31
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5493000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5001000
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-11248000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11397000

Files In Submission

Name View Source Status
0001193125-17-073383-index-headers.html Edgar Link pending
0001193125-17-073383-index.html Edgar Link pending
0001193125-17-073383.txt Edgar Link pending
0001193125-17-073383-xbrl.zip Edgar Link pending
d310331d10k.htm Edgar Link pending
d310331dex109.htm Edgar Link pending
d310331dex211.htm Edgar Link pending
d310331dex231.htm Edgar Link pending
d310331dex311.htm Edgar Link pending
d310331dex312.htm Edgar Link pending
d310331dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g310331g0303134535831.jpg Edgar Link pending
g310331g0303134538062.jpg Edgar Link pending
g310331g29m21.jpg Edgar Link pending
g310331g29w67.jpg Edgar Link pending
g310331g61e75.jpg Edgar Link pending
g310331g66g56.jpg Edgar Link pending
g310331g69g71.jpg Edgar Link pending
g310331g81y26.jpg Edgar Link pending
g310331g95f32.jpg Edgar Link pending
ptgx-20161231.xml Edgar Link completed
ptgx-20161231.xsd Edgar Link pending
ptgx-20161231_cal.xml Edgar Link unprocessable
ptgx-20161231_def.xml Edgar Link unprocessable
ptgx-20161231_lab.xml Edgar Link unprocessable
ptgx-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending